Advertisement
U.S. markets open in 2 hours 3 minutes

MediciNova, Inc. (MNOV)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.3500+0.0500 (+3.85%)
At close: 04:00PM EDT
1.3500 0.00 (0.00%)
After hours: 04:00PM EDT

MediciNova, Inc.

4275 Executive Square
Suite 300
La Jolla, CA 92037
United States
858 373 1500
https://www.medicinova.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Dr. Yuichi Iwaki M.D., Ph.D.Co-Founder, President, CEO & Executive Director933.05kN/A1950
Dr. Kazuko Matsuda M.D., M.P.H., Ph.D.Chief Medical Officer & Director653.65kN/A1966
Mr. Jason J. Kruger CPACFO & Principal Financial OfficerN/AN/A1978
Dr. David H. Crean M.B.A., Ph.D.Chief Business OfficerN/AN/A1965
Mr. John O'Neil CPAControllerN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Corporate Governance

MediciNova, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 8. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.